Funds cluster with a few high-volume names,


The short squeeze flavor is obvious.
#1 RONIN +29.4%
Funding rate -0.44%, Open Interest +440.2%.
Shorts are still paying to hold on tight,
Trading volume $352M, the hottest on the order book.
#2 EDEN +22.4%
Funding rate -0.164%, Open Interest +34.9%.
Price increase and trading volume are both online,
Not a pulse without volume.
#3 PLAY +19.9%
Open Interest +69.5%, Taker 0.91.
Chasing prices isn’t extreme,
But positions are flooding in quickly.
#4 MBOX +17.4%
Complete Open Interest missing, funding rate missing.
Just looking at the increase puts it in the front row,
Follow-up depends on volume confirmation.
#5 ONDO +13.5%
Complete Open Interest missing, funding rate missing.
More mainstream beta performance,
Less hot than the top three clusters.
#6 BOME +12.4%
Complete Open Interest missing, funding rate missing.
Emotional elasticity still present,
But order book details are insufficient.
#7 IDOL +12.3%
Complete Open Interest missing, funding rate missing.
Price increase is among the top,
But contract verification is temporarily lacking.

Complete Open Interest missing, funding rate missing.
Name popularity continues,
But deep data is insufficient.
#9 LIT +11.3%
Complete Open Interest missing, funding rate missing.
Following the market correction,
No core signals seen yet.
#10 AKT +11.1%
Complete Open Interest missing, funding rate missing.
Price increase enters the top ten,
More like a rebound rhythm.
Clear candidates for short squeeze:
RONIN, EDEN, PLAY.
Especially RONIN, the fee is too extreme,
This kind of structure is more likely to trigger a move the longer it drags.
Overall, it’s a strong cluster of holdings,
Focus on RONIN’s continuation,
Watch EDEN and PLAY for position changes.
Using Claude Opus 4.7
Model generated.
Claude is AI and can make mistakes.
Please double-check responses.
EDEN56.85%
MBOX5.23%
ONDO-4.05%
BOME0.84%
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned